complement C5 binding
Showing 1 - 25 of 6,124
Complement C5a Receptors in Hidradenitis Suppurativa
Recruiting
- Hidradenitis Suppurativa
-
Redwood City, CaliforniaStanford University
Jun 27, 2022
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD Trial
Not yet recruiting
- Neuromyelitis Optica Spectrum Disorder
- +2 more
- (no location specified)
Jul 21, 2023
Covid19, Thrombotic Microangiopathies, Acute Kidney Injury Trial in Boston (Ravulizumab)
Active, not recruiting
- Covid19
- +2 more
-
Boston, MassachusettsBrigham and Women's Hospital
Dec 31, 2022
Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy, IgA Nephropathy Trial in Korea, Republic of, New Zealand, Thailand
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- +2 more
- ARO-C3
- Placebo
-
Camperdown, New South Wales, Australia
- +19 more
Sep 13, 2022
Donor-specific Antibodies After Liver Transplantation
Completed
- Liver Transplant
-
Lille, FranceCHRU, Hôpital Claude Huriez
Mar 24, 2021
Geographic Atrophy, Macular Degeneration Trial in Dallas (Avacincaptad pegol 2 mg intravitreal injection)
Not yet recruiting
- Geographic Atrophy
- Macular Degeneration
- Avacincaptad pegol 2 mg intravitreal injection
-
Dallas, TexasRetina Foundation of the Southwest
Sep 7, 2022
Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy Trial in Ranica (C3NEF assay)
Not yet recruiting
- Hemolytic-Uremic Syndrome
- +2 more
- C3NEF assay
-
Ranica, BG, ItalyCentro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Da
Aug 9, 2023
Generalized Myasthenia Gravis Trial in United States
Recruiting
- Generalized Myasthenia Gravis
-
Phoenix, Arizona
- +9 more
Dec 16, 2020
Bullous Pemphigoid Trial in Worldwide (nomacopan (rVA576), Placebo)
Withdrawn
- Bullous Pemphigoid
- nomacopan (rVA576)
- Placebo
-
Los Angeles, California
- +11 more
Oct 18, 2022
Pharmacodynamics of Eculizumab in Paroxysmal Nocturnal
Completed
- Paroxysmal Nocturnal Hemoglobinuria
- +2 more
- Blood collection for measurement of eculizumab peak concentrations
-
Nijmegen, NetherlandsRadboudumc
Aug 23, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial in Whittier (Ravulizumab, Pozelimab, Cemdisiran)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- Ravulizumab
- +2 more
-
Whittier, California
- +8 more
Nov 29, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial (Pozelimab, Cemdisiran)
Not yet recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- (no location specified)
Feb 22, 2023
Complement Deficiency, Antibody Deficiency, Chronic Sinus Infection Trial in France (Immunological diagnosis tests)
Terminated
- Complement Deficiency
- +9 more
- Immunological diagnosis tests
-
Armentières, France
- +18 more
Sep 16, 2020
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19) Trial (AMY-101, WFI 5% glucose)
Not yet recruiting
- Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
- AMY-101
- WFI 5% glucose
- (no location specified)
Feb 19, 2021
Generalized Myasthenia Gravis Trial (zilucoplan (RA101495))
Not yet recruiting
- Generalized Myasthenia Gravis
- zilucoplan (RA101495)
- (no location specified)
Aug 22, 2022
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- BCX9930
- +2 more
-
Paris, France
- +6 more
Dec 15, 2022
Atypical Hemolytic Uremic Syndrome Trial (Iptacopan)
Not yet recruiting
- Atypical Hemolytic Uremic Syndrome
- (no location specified)
Jun 29, 2023
Wet Age-related Macular Degeneration Trial in Hungary, Latvia, United States (Zimura, Lucentis)
Completed
- Wet Age-related Macular Degeneration
-
Phoenix, Arizona
- +27 more
Feb 3, 2022
Preterm Birth and Biomarkers for Cardiovascular Disease
Completed
- Preterm Birth
- Cardiovascular Diseases
- No intervention
-
Uppsala, SwedenDepartment of Medical Sciences, Uppsala University
Jan 23, 2023